Department of Medicine, SMS Medical College, Jaipur, India.
Department of Medicine, SMS Medical College, Jaipur, India.
J Glob Antimicrob Resist. 2020 Sep;22:864-865. doi: 10.1016/j.jgar.2020.07.022. Epub 2020 Aug 7.
The potentiality of Hydroxychloroquine (HCQ) for pre-exposure prophylaxis against SARS-CoV-2 has not been explored in randomized controlled trials. However, there is rationale behind this potentiality in terms of demonstrated in-vitro effect of HCQ against SARS-CoV-2, safety profile of HCQ in healthy individuals and a recent observational study demonstrating benefits of HCQ prophylaxis in terms of a significant reduction (>80%) in the odds of SARS-CoV-2 infection in the health-care workers (HCWs) with the intake of six or more doses of HCQ prophylaxis as per the guidelines of the National Task Force for COVID-19 in India. Hence, pre-exposure prophylaxis with HCQ in appears to be a reasonable strategy in the current scenario for prevention of SARS-CoV-2 infection in healthy HCWs.
羟氯喹（HCQ）预防 SARS-CoV-2 的潜力尚未在随机对照试验中得到探索。然而，HCQ 具有以下潜在作用：已证明 HCQ 在体外对 SARS-CoV-2 具有抑制作用、HCQ 在健康个体中的安全性特征，以及最近的一项观察性研究表明，HCQ 预防可带来益处，可显著降低（>80%）根据印度国家 COVID-19 工作队的指南，接受 6 剂或更多 HCQ 预防剂量的医护人员（HCWs）感染 SARS-CoV-2 的几率。因此，在当前情况下，HCQ 暴露前预防对于预防健康 HCWs 感染 SARS-CoV-2 似乎是一种合理的策略。
